Market Cap: $28.73B
II
Insmed Incorporated
INSM
NASDAQ (NASDAQ Global Select)USD
Market Cap: $28.73B
In a notable development, Insmed Incorporated (Ticker: INSM) appoints Samuele Butera as the new Senior Vice President for Global Respiratory, strong-arming its focus on respiratory therapies amid shif…
Insmed (Ticker: INSM) announces the appointment of Samuele Butera as the Senior Vice President and General Manager of its Global Respiratory division, bolstering its leadership team at a critical junc…
Insmed Inc (Ticker: INSM) is in a transformative phase as it navigates recent changes in its investor landscape and the impact on its business model. The company, known for its focus on rare diseases,…
Insmed Inc. (Ticker: INSM) is experiencing significant excitement around its newly launched medication, brensocatib, due to encouraging feedback from physicians. The early responses suggest a broad pr…
Insmed Incorporated (Ticker: INSM) continues to solidify its presence in the biopharmaceuticals sector through strategic hiring and promising clinical trial results. Recently, the company announced th…
Insmed (Ticker: INSM) is navigating strategic financial adjustments to bolster its operations. Recently, the company has filed an automatic shelf registration, aiming to issue common stock and debt se…
Insmed Incorporated demonstrates a strong commitment to advancing treatment for pulmonary diseases, as evidenced by its participation in the upcoming American Thoracic Society International Conference…
Insmed Incorporated, known for its commitment to developing innovative therapies in the biotech sector, faces a significant setback as its Phase 2b clinical trial results on brensocatib for hidradenit…
Promising Advancements in Mycobacterium Avium Complex Treatment Insmed Incorporated is making significant strides in the treatment of Mycobacterium avium complex (MAC) lung infections, a condition kno…
Insmed's Commitment to Workforce Growth through Inducement Awards Insmed Incorporated, a global biopharmaceutical leader based in Bridgewater, New Jersey, recently takes a significant step in its grow…
Insmed's Commitment to Talent Acquisition and Employee Retention Insmed Incorporated, a prominent biopharmaceutical company based in Bridgewater, New Jersey, demonstrates its commitment to attracting…
Insmed Strengthens Workforce with Inducement Awards in Biopharmaceutical Sector On March 5, 2026, Insmed Incorporated, a leading biopharmaceutical company headquartered in Bridgewater, New Jersey, ann…
Analyst chorus flags strategic questions at Insmed Divergent analyst views highlight regulatory and clinical uncertainty Insmed is facing a split set of professional assessments as 16 analysts issue m…
Insmed times pre‑market Q4 disclosure to frame operational priorities Q4 filing frames commercial and development priorities Insmed releases its fourth‑quarter 2025 results on Feb. 19, 2026 at 07:00 a…
Insmed frames Q4 report as a strategic update on commercial traction and pipeline progress Insmed is issuing its fourth-quarter 2025 results in a timed release that serves primarily as a strategic upd…
Insmed times quarterly disclosure to outline commercial and pipeline progress Insmed issues its fourth-quarter 2025 results on Feb. 19, 2026 at 07:00 ET, delivering the routine mix of financial figure…
Management to outline pulmonary and inflammatory strategy at two March conferences Insmed Incorporated is presenting its clinical and commercial strategy at two major healthcare investor conferences i…
Insmed to present R&D strategy and pipeline at two March investor conferences Insmed Inc. says company management will present its clinical and research strategy at two industry conferences in March 2…
Insmed’s Promising Pipeline: Fueling Growth in Rare Lung Diseases Insmed's recent performance highlights the company's significant advancements in treating rare lung diseases, particularly with the co…
Insmed's Brinsupri Drives Significant Market Growth Insmed is currently experiencing a remarkable transformation in the biotech landscape, primarily fueled by the success of its lead product, Brinsupr…
Insmed's Strategic Focus on Innovative Respiratory Treatments Insmed Incorporated, a biopharmaceutical company dedicated to developing therapies for serious diseases, highlights its commitment to addr…
Insmed's Strategic Vision for Advancing Respiratory Therapies Insmed Incorporated, a biopharmaceutical company dedicated to innovative treatments for serious diseases, showcases a robust financial per…
Insmed’s Commitment to Innovative Therapies in Serious Diseases Insmed Incorporated, a biopharmaceutical company headquartered in Bridgewater, New Jersey, stands at the forefront of developing innovat…
### Insmed's Commitment to Innovative Therapies: A Focus on Patient-Centric Solutions Insmed Incorporated, a biopharmaceutical company headquartered in Bridgewater, New Jersey, is making significant s…
Insmed Discontinues Phase 2b Study of Brensocatib for Chronic Rhinosinusitis, Shifts Focus to New Therapy Insmed Incorporated, a biopharmaceutical company renowned for its innovative treatment approac…
Insmed Discontinues Brensocatib Study but Forges Ahead with New Monoclonal Antibody Acquisition Insmed Incorporated, a biopharmaceutical company focused on innovative therapies for severe diseases, ha…
Insmed Faces Setback in Chronic Rhinosinusitis Study, Eyes New Opportunities with INS1148 Insmed Incorporated, a biopharmaceutical company dedicated to developing innovative therapies for serious dise…
Insmed Sees Decline in Short Interest, Reflecting Investor Sentiment Shift Insmed Inc. experiences a significant decline in its short interest, with figures dropping by 16.1% since the last reporting…
Insmed’s Commitment to Talent Acquisition through Strategic Inducement Awards Insmed Incorporated, a biopharmaceutical company based in Bridgewater, New Jersey, reaffirms its commitment to talent acqu…
Insmed Expands Workforce with Inducement Awards to Enhance Innovation in Biopharmaceuticals Insmed Incorporated, a biopharmaceutical company based in Bridgewater, New Jersey, takes significant steps t…
Insmed's Commitment to Talent Acquisition and Innovative Therapies Insmed Incorporated, a biopharmaceutical company based in Bridgewater, New Jersey, continues to prioritize talent acquisition as a fu…
Insmed's BRINSUPRI Approval: A Historic Step for Non-Cystic Fibrosis Bronchiectasis Treatment in Europe Insmed Incorporated, a biopharmaceutical company dedicated to developing treatments for serious…
Insmed Secures European Approval for BRINSUPRI, Pioneering Treatment for Non-Cystic Fibrosis Bronchiectasis Insmed Incorporated announces a significant milestone with the European Commission's approva…
Insmed's Global Day of Good Highlights Commitment to Community Service Insmed Incorporated, a biopharmaceutical company based in Bridgewater, N.J., showcases its dedication to community engagement dur…
Insmed's Commitment to Community Service Shines on Global Day of Good Insmed Incorporated, a biopharmaceutical leader based in Bridgewater, N.J., showcases its commitment to corporate social responsib…
Insmed's Global Day of Good: A Commitment to Community Impact Insmed Incorporated, a biopharmaceutical powerhouse based in Bridgewater, N.J., celebrates its fourth annual Global Day of Good on Novembe…
Insmed's Strategic Positioning in Biopharmaceuticals Amid Economic Challenges Insmed is currently at a pivotal moment in the biopharmaceutical industry, where the need for innovative therapies is incr…
Insmed's Strategic Positioning in the Biopharmaceutical Landscape Insmed Incorporated, a leader in the biopharmaceutical industry, continues to focus on developing innovative therapies for patients wi…
Insmed Faces Investor Scrutiny Amid Bearish Sentiment Insmed, a biopharmaceutical company specializing in innovative therapies for rare diseases, currently experiences heightened scrutiny from investo…
Insmed Faces Bearish Sentiment Amid Uncertain Future Developments Insmed, a biopharmaceutical company specializing in innovative therapies for rare diseases, finds itself at a critical juncture as sig…
Insmed's Analyst Coverage Highlights Industry Dynamics In recent months, Insmed has attracted the attention of 20 analysts who provide a diverse array of ratings, reflecting the complexities and chall…
Insmed's Market Position: A Complex Landscape of Analyst Opinions In recent months, Insmed has become a focal point for analysts assessing the biopharmaceutical landscape. Over the past three months,…
Emerging M&A Landscape: Insmed Positioned as a Key Target in Biopharmaceuticals In the wake of significant merger and acquisition (M&A) activity on Wall Street, Insmed stands out as a noteworthy poten…
M&A Landscape Poised for Growth: Insmed at the Forefront The recent surge in mergers and acquisitions (M&A) activity is reshaping the landscape for biopharmaceutical companies, with Insmed emerging as…
Insmed Faces Bearish Sentiment Amid Unusual Trading Activity Recent analysis reveals a notable shift in market sentiment surrounding Insmed, a biopharmaceutical company focused on developing innovativ…
Insmed Faces Institutional Skepticism Amid Unusual Trading Activity Insmed finds itself at a critical juncture as financial institutions exhibit a pronounced bearish sentiment towards the company. Rec…
Insmed Showcases Innovative Therapies at European Respiratory Society Congress Insmed Incorporated, a biopharmaceutical company focused on developing therapies for serious diseases, prepares to presen…
Insmed Advances Respiratory Disease Treatment at ERS Congress Insmed Incorporated, a biopharmaceutical company specializing in innovative therapies for serious diseases, showcases its commitment to ad…
Insmed Strengthens Workforce with Inducement Awards to New Employees Insmed Incorporated, a biopharmaceutical company located in Bridgewater, New Jersey, is making significant strides in enhancing its…
Insmed's Diverse Analyst Ratings Reflect Industry Complexity Insmed, a biopharmaceutical company focused on developing innovative therapies, garners attention from analysts as it navigates a competiti…